# A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

> **NCT05797753** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 16 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Healthy Volunteer

## Interventions

- **DRUG:** SAR443820
- **DRUG:** SAR443820
- **DRUG:** Erythromycin ethyl succinate
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT05797753
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-18
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05797753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05797753, "A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05797753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*